JOURNAL ARTICLE

CSAT: Federal BOP facilities must provide methadone.

  • Published In: Alcoholism & Drug Abuse Weekly, 2023, v. 35, n. 17. P. 5 1 of 3

  • Database: Academic Search Ultimate 2 of 3

  • Authored By: Knopf, Alison 3 of 3

Abstract

"All three medications" to treat opioid use disorder must be available in federal Bureau of Prisons (BOP) facilities, said Yngvild Olsen, M.D. at the Rx and Illicit Drug Summit last month in Atlanta. Olsen, director of the Center for Substance Abuse Treatment (CSAT) at the Substance Abuse and Mental Health Services Administration (SAMHSA), noted that the three medications include methadone ("the most heavily regulated,"), buprenorphine (now easier to prescribe because of the elimination of the X‐waiver), and naltrexone ("especially injectable naltrexone," or Vivitrol). "All three have been heavily studied," Olsen told the audience, adding that she was "not necessarily comparing one against another," but that the key is to provide access to all three. [ABSTRACT FROM AUTHOR]

Additional Information

  • Source:Alcoholism & Drug Abuse Weekly. 2023/05, Vol. 35, Issue 17, p5
  • Document Type:Article
  • Subject Area:Health and Medicine
  • Publication Date:2023
  • ISSN:1042-1394
  • DOI:10.1002/adaw.33760
  • Accession Number:163411178
  • Copyright Statement:Copyright of Alcoholism & Drug Abuse Weekly is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Looking to go deeper into this topic? Look for more articles on EBSCOhost.